J Am Coll Clin Pharm. 2021 Nov 08; doi: 10.1002/jac5.1556. Epub 2021 Nov 08.
Pharmacists and opioid use disorder care during COVID-19: Call for action.
Journal of the American College of Clinical Pharmacy : JACCP
Insaf Mohammad, Dena Berri, Victoria Tutag Lehr
Affiliations
Affiliations
- Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan USA.
- Ambulatory Care Clinical Pharmacy Beaumont Hospital, Dearborn Dearborn Michigan USA.
PMID: 34909605
PMCID: PMC8661525 DOI: 10.1002/jac5.1556
Abstract
Opioid use disorder (OUD) is a chronic relapsing condition characterized by problematic opioid use causing significant impairment in daily life. Medication for opioid use disorder using buprenorphine, methadone, and naltrexone with behavioral therapy reduces illicit opioid use and risk of overdose death. Despite evidence and decades of experience, barriers limit access to treatment and care for individuals with OUD. Barriers include a lack of treatment centers particularly in rural areas, regulations on buprenorphine prescribing, and stigma from the community and health care professionals. While many barriers are longstanding, the coronavirus disease 2019 (COVID-19) pandemic-forced isolation and associated stress has exacerbated challenges for individuals with mental health conditions such as OUD. Pharmacists are well-positioned to bridge existing gaps in OUD care, particularly during the COVID-19 pandemic. Roles for pharmacists include OUD risk identification and screening, referral of patients to treatment and support programs, ensuring medication access, expanding naloxone access, and advocacy initiatives. This review article identifies barriers to care for patients with OUD during the COVID-19 pandemic and explores opportunities and resources for pharmacists to improve OUD care during the pandemic and beyond.
© 2021 Pharmacotherapy Publications, Inc.
Keywords: COVID‐19; access to treatment; medication access; opioid use disorder; pharmacist
Conflict of interest statement
The authors declare no conflict of interest.
References
- Am J Health Syst Pharm. 2016 May 1;73(9):e267-70 - PubMed
- J Addict Med. 2020 Jul/Aug;14(4):e1-e3 - PubMed
- Addict Sci Clin Pract. 2021 Jan 7;16(1):4 - PubMed
- J Pain Res. 2021 Apr 27;14:1161-1169 - PubMed
- JAMA Netw Open. 2020 Jun 1;3(6):e209085 - PubMed
- Addiction. 2021 Jul;116(7):1805-1816 - PubMed
- J Addict Med. 2020 Jul/Aug;14(4):e8-e9 - PubMed
- Harm Reduct J. 2020 May 6;17(1):26 - PubMed
- JAMA Netw Open. 2020 Feb 5;3(2):e1920843 - PubMed
- Drug Alcohol Depend. 2020 Mar 27;211:107968 - PubMed
- JAMA Netw Open. 2019 Jun 5;2(6):e196373 - PubMed
- J Med Toxicol. 2019 Oct;15(4):307-309 - PubMed
- J Pain Symptom Manage. 2020 Aug;60(2):e48-e51 - PubMed
- J Addict Med. 2020 Dec;14(6):e287-e289 - PubMed
- N Engl J Med. 2020 Aug 20;383(8):703-705 - PubMed
- Prev Chronic Dis. 2020 Jul 23;17:E69 - PubMed
- J Am Pharm Assoc (2003). 2020 Jan - Feb;60(1):178-194 - PubMed
- Ann Intern Med. 2020 Jul 7;173(1):59-60 - PubMed
- J Addict Med. 2019 Sep/Oct;13(5):403-407 - PubMed
- Subst Abus. 2020;41(2):147-149 - PubMed
- Drug Alcohol Depend. 2018 Oct 1;191:1-5 - PubMed
- J Subst Abuse Treat. 2019 Sep;104:148-157 - PubMed
- JAMA Psychiatry. 2014 Nov;71(11):1246-53 - PubMed
- J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2S):S5-S7 - PubMed
- Addict Sci Clin Pract. 2019 Sep 2;14(1):30 - PubMed
- Subst Abuse. 2017 Jun 13;11:1178221817699247 - PubMed
- Am J Health Syst Pharm. 2021 Mar 18;78(7):613-618 - PubMed
- J Am Pharm Assoc (2003). 2020 May - Jun;60(3S):S20-S28.e4 - PubMed
- J Rural Health. 2019 Jan;35(1):108-112 - PubMed
- Int J Drug Policy. 2020 Nov;85:102701 - PubMed
- J Addict Med. 2020 Jul/Aug;14(4):e4-e5 - PubMed
- J Subst Abuse Treat. 2021 Mar;122:108210 - PubMed
- Pharmacy (Basel). 2019 Jun 12;7(2): - PubMed
- JAMA Netw Open. 2019 May 3;2(5):e193209 - PubMed
- Drug Alcohol Depend. 2018 Aug 1;189:131-138 - PubMed
- J Subst Abuse Treat. 2021 Mar;122:108214 - PubMed
- Inj Prev. 2021 Oct;27(5):500-505 - PubMed
- Open Forum Infect Dis. 2020 Oct 20;7(11):ofaa503 - PubMed
- N Engl J Med. 2018 Jul 5;379(1):7-8 - PubMed
Publication Types